OBJECTIVE: To interfere with the improper prescriptions of Chinese herbal pieces issued by the outpatient doctors so as to reduce the doctor's prescription error rate and ensure the safety of medication for patien...OBJECTIVE: To interfere with the improper prescriptions of Chinese herbal pieces issued by the outpatient doctors so as to reduce the doctor's prescription error rate and ensure the safety of medication for patients. METHODS:Based on Prescription Administrative Policy, Management Standard of Chinese Herbal Pieces in Hospital, and Beijing Chinese Herbal Pieces Dispensing Regulation, 2000 prescriptions were collected and analyzed according to the different intervention, and solutions were put forward for a variety of reasons. RESULTS: In 2000 prescriptions, there were 932 prescriptions containing toxic drug overdose without double signature, 577 prescriptions of dose error, 282 prescriptions of ingredients error, 85 prescriptions with wrong route of administration, 73 prescriptions of herb incompatibility without double signature, and 51 prescriptions with repeat herbs, accounting for 46.5%, 28.85%, 14.1%, 4.25%, 3.65% and2.55% of the total number of prescriptions respectively. After the intervention of pharmacists, 2000 prescriptions were all successfully intervened to protect the safety of medication. CONCLUSIONS: TCM pharmacist should double check prescriptions with errors issued by doctors, so as to reduce the prescription error rate, and ensure the safety of medication and rehabilitation of patients, and then improve values of pharmacists.展开更多
Objective To provide suggestions for optimizing the sampling management of Chinese herbal pieces and improving the quality Chinese herbal pieces.Methods Logical reasoning method was used to analyze the problems in the...Objective To provide suggestions for optimizing the sampling management of Chinese herbal pieces and improving the quality Chinese herbal pieces.Methods Logical reasoning method was used to analyze the problems in the drug spot check of Chinese herbal pieces based on the data of drug quality published by the National Medical Products Administration from 2013 to 2021,combined with the current provisions and implementation of drug spot check management in China.Results and Conclusion At present,there are some problems in the drug spot check of Chinese herbal pieces,such as fewer varieties of Chinese herbal pieces in the national drug spot check,the unreasonable sampling links,the insufficient territorial management in some areas,and error-prone sample extraction.It is suggested that the actual quantity and overall quality of Chinese herbal pieces should be fully considered in the formulation of sampling plan.Besides,the variety coverage of drug spot check of traditional Chinese medicine should be strengthened.In the planning,the sampling links shall be made as a whole,and the credit rating and distribution of drug production,operation and use units within the jurisdiction shall be fully combined.While strengthening the sampling management at the production end in areas with concentrated industries,regional special drug spot check should be carried out or the administrative forces at the provincial,municipal and county levels should be fully mobilized to avoid local protection.In the assigned tasks,the name of Chinese herbal pieces should be accurately expressed to avoid the sampling errors of Chinese herbal pieces with the same original medicinal materials and different processing methods.展开更多
“Long-Dan”is an important traditional Chinese medicinal(TCM)herb used widely for the treatment of inflammation,hepatitis,rheumatism,cholecystitis,and tuberculosis.In the Chinese Pharmacopoeia,the roots and rhizomes ...“Long-Dan”is an important traditional Chinese medicinal(TCM)herb used widely for the treatment of inflammation,hepatitis,rheumatism,cholecystitis,and tuberculosis.In the Chinese Pharmacopoeia,the roots and rhizomes of four species from the genus Gentiana(Gentianaceae)are recorded as the original materials of“Long-Dan”,called Gentianae Radix et Rhizoma.The species included G.manshurica,G.scabra,G.triflora and G.rigescens,which are distributed in different areas of China.Though iridoid and secoiridoid glucosides were reported as the main constituents in“Long-Dan”,these four different species also resulted in different minor components,which may related to their pharmacological activities.Herein,we summarized the herbal textual study,distribution,chemical constituents,biological investigation and quality control of the recorded“Long-Dan”origins in Chinese Pharmacopoeia during the period 1960 to 2011.展开更多
In order to assure the safety and efficacy of the Chinese Medicines in Europe, the quality of TCM herbals should be guaranteed so that they can be freely imported in the European Union and other Western European Count...In order to assure the safety and efficacy of the Chinese Medicines in Europe, the quality of TCM herbals should be guaranteed so that they can be freely imported in the European Union and other Western European Countries which are signatories of the European Pharmacopoeia Convention. Consequently, new Ph Eur TCM herbal drug Monographs should be elaborated, based on preexisting Monographs in the Chinese Pharmacopoeia(Ch P) 2010.Such a program has been inaugurated in 2005 by the Ph Eur Groups of Experts 13 A and B(Phytochemistry). Since then good progress has been made, elaborating of about one third of the originally proposed 100 TCM herbals being identified as important monographs for the European Market. Taking into account the many challenges still laying ahead, the establishment of a specialized Working Party(WP) on TCM with specialists and experts from many EU Member States has been decided by the Ph Eur Commission in 2008 which is highly active ever since in the examination and elaboration of new TCM herbal drug monographs, primarily to assure the safety of the European patient and further to provide quality parameters extremely important for all registration and licensing procedures of the respective National Authorities all over Europe.This paper is a survey of results and difficulties obtained so far which has been encountered meanwhile in the elaboration process by the Ph Eur TCM WP of these monographs and will discuss these in detail. Moreover the role of Ph Eur TCM monographs in the European community is addressed.展开更多
This review is briefly to recall the history of research and development (R&D) of Chinese materia medica (CMM) and to discuss the challenges of Chinese traditional and herbal medicines (CTHM) facing the modern sci...This review is briefly to recall the history of research and development (R&D) of Chinese materia medica (CMM) and to discuss the challenges of Chinese traditional and herbal medicines (CTHM) facing the modern science and technology. The R&D of CTHM is thought to be an important pathway for new drug discovery. Since1949, about 140 approved new drugs have been developed, among which about 80 originated directly or indirectly from medicinal plants. CTHM has gained interest from the international medical, biomedical, and pharmaceutical institutions as a valuable source of potential medicines. For the modernization of CMM and innovative research of CTHM, there are following challenges to be faced: (1) to evaluate the efficacy, pharmacological properties, action mechanism, and active chemical constituents; (2) to develop new methodologies for the quality and safety of CTHM; (3) to apply new '-omics' techniques to accelerate drug discoveries developed from CTHM; and (4) to apply international practices including good agricultural practice, good manufacturing practice, good laboratory practice, and good clinical practice in the R&D of CTHM.展开更多
文摘OBJECTIVE: To interfere with the improper prescriptions of Chinese herbal pieces issued by the outpatient doctors so as to reduce the doctor's prescription error rate and ensure the safety of medication for patients. METHODS:Based on Prescription Administrative Policy, Management Standard of Chinese Herbal Pieces in Hospital, and Beijing Chinese Herbal Pieces Dispensing Regulation, 2000 prescriptions were collected and analyzed according to the different intervention, and solutions were put forward for a variety of reasons. RESULTS: In 2000 prescriptions, there were 932 prescriptions containing toxic drug overdose without double signature, 577 prescriptions of dose error, 282 prescriptions of ingredients error, 85 prescriptions with wrong route of administration, 73 prescriptions of herb incompatibility without double signature, and 51 prescriptions with repeat herbs, accounting for 46.5%, 28.85%, 14.1%, 4.25%, 3.65% and2.55% of the total number of prescriptions respectively. After the intervention of pharmacists, 2000 prescriptions were all successfully intervened to protect the safety of medication. CONCLUSIONS: TCM pharmacist should double check prescriptions with errors issued by doctors, so as to reduce the prescription error rate, and ensure the safety of medication and rehabilitation of patients, and then improve values of pharmacists.
文摘Objective To provide suggestions for optimizing the sampling management of Chinese herbal pieces and improving the quality Chinese herbal pieces.Methods Logical reasoning method was used to analyze the problems in the drug spot check of Chinese herbal pieces based on the data of drug quality published by the National Medical Products Administration from 2013 to 2021,combined with the current provisions and implementation of drug spot check management in China.Results and Conclusion At present,there are some problems in the drug spot check of Chinese herbal pieces,such as fewer varieties of Chinese herbal pieces in the national drug spot check,the unreasonable sampling links,the insufficient territorial management in some areas,and error-prone sample extraction.It is suggested that the actual quantity and overall quality of Chinese herbal pieces should be fully considered in the formulation of sampling plan.Besides,the variety coverage of drug spot check of traditional Chinese medicine should be strengthened.In the planning,the sampling links shall be made as a whole,and the credit rating and distribution of drug production,operation and use units within the jurisdiction shall be fully combined.While strengthening the sampling management at the production end in areas with concentrated industries,regional special drug spot check should be carried out or the administrative forces at the provincial,municipal and county levels should be fully mobilized to avoid local protection.In the assigned tasks,the name of Chinese herbal pieces should be accurately expressed to avoid the sampling errors of Chinese herbal pieces with the same original medicinal materials and different processing methods.
基金supported by Science and Technology Planning Project of Yunnan Province(2010CD106)the 973 Program of Ministry of Science and Technology of China(2011CB915503)+1 种基金the State Key Laboratory of Phytochemistry and Plant Resources in West China,Chinese Academy of Sciences(P2010-ZZ03)The Fourteenth Candidates of the Young Academic Leaders of Yunnan Province(Min XU,2011CI044).
文摘“Long-Dan”is an important traditional Chinese medicinal(TCM)herb used widely for the treatment of inflammation,hepatitis,rheumatism,cholecystitis,and tuberculosis.In the Chinese Pharmacopoeia,the roots and rhizomes of four species from the genus Gentiana(Gentianaceae)are recorded as the original materials of“Long-Dan”,called Gentianae Radix et Rhizoma.The species included G.manshurica,G.scabra,G.triflora and G.rigescens,which are distributed in different areas of China.Though iridoid and secoiridoid glucosides were reported as the main constituents in“Long-Dan”,these four different species also resulted in different minor components,which may related to their pharmacological activities.Herein,we summarized the herbal textual study,distribution,chemical constituents,biological investigation and quality control of the recorded“Long-Dan”origins in Chinese Pharmacopoeia during the period 1960 to 2011.
文摘In order to assure the safety and efficacy of the Chinese Medicines in Europe, the quality of TCM herbals should be guaranteed so that they can be freely imported in the European Union and other Western European Countries which are signatories of the European Pharmacopoeia Convention. Consequently, new Ph Eur TCM herbal drug Monographs should be elaborated, based on preexisting Monographs in the Chinese Pharmacopoeia(Ch P) 2010.Such a program has been inaugurated in 2005 by the Ph Eur Groups of Experts 13 A and B(Phytochemistry). Since then good progress has been made, elaborating of about one third of the originally proposed 100 TCM herbals being identified as important monographs for the European Market. Taking into account the many challenges still laying ahead, the establishment of a specialized Working Party(WP) on TCM with specialists and experts from many EU Member States has been decided by the Ph Eur Commission in 2008 which is highly active ever since in the examination and elaboration of new TCM herbal drug monographs, primarily to assure the safety of the European patient and further to provide quality parameters extremely important for all registration and licensing procedures of the respective National Authorities all over Europe.This paper is a survey of results and difficulties obtained so far which has been encountered meanwhile in the elaboration process by the Ph Eur TCM WP of these monographs and will discuss these in detail. Moreover the role of Ph Eur TCM monographs in the European community is addressed.
文摘This review is briefly to recall the history of research and development (R&D) of Chinese materia medica (CMM) and to discuss the challenges of Chinese traditional and herbal medicines (CTHM) facing the modern science and technology. The R&D of CTHM is thought to be an important pathway for new drug discovery. Since1949, about 140 approved new drugs have been developed, among which about 80 originated directly or indirectly from medicinal plants. CTHM has gained interest from the international medical, biomedical, and pharmaceutical institutions as a valuable source of potential medicines. For the modernization of CMM and innovative research of CTHM, there are following challenges to be faced: (1) to evaluate the efficacy, pharmacological properties, action mechanism, and active chemical constituents; (2) to develop new methodologies for the quality and safety of CTHM; (3) to apply new '-omics' techniques to accelerate drug discoveries developed from CTHM; and (4) to apply international practices including good agricultural practice, good manufacturing practice, good laboratory practice, and good clinical practice in the R&D of CTHM.
